Credit: Glaukos. Epioxa does not require the removal of the corneal epithelium, a step usually required by traditional corneal cross-linking procedures, thereby minimizing pain and recovery time.

Please provide your email address to receive an email when new articles are posted on . Delaying the need for a corneal transplant is critical in pediatric patients. Young patients must be treated ...

In our practice, corneal transplantation for keratoconus, whether that is penetrating keratoplasty or deep anterior lamellar ...

(MASS APPEAL) – If you’ve been diagnosed with Keratoconus then Corneal Cross Linking might get you back to better eyesight. Mass Appeal’s Patrick Berry joined Dr. John P. Frangie, MD to learn more.

Glaukos Corporation GKOS recently announced the commercial availability of Epioxa, marking a significant milestone in its corneal health portfolio. The therapy stands out as the first FDA-approved, ...

Glaukos Corporation recently announced that its technologies were featured across scientific programming at the American ...

“The femtosecond laser lets us manufacture each segment to exact specifications for each patient,” said Dr Cronin. “Combined with the Brisbane nomogram, this gives us a reproducible, tailored solution ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for ...

Understanding Keratoconus and Corneal Cross Linking Mass Appeal / May 16, 2025 / 02:14 PM EDT If you've been diagnosed with Keratoconus then Corneal Cross Linking might get you back to better eyesight ...